BV
BVF.F Bausch Health Companies Inc
- Market cap
- EUR 2.81B
- P/E
- -
- P/B
- 18.34x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BVF.F undervalued?
Graham numberThe Graham number of Bausch Health Companies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bausch Health Companies Inc fundamental analysis
No fundamental analysis for Bausch Health Companies Inc yet.
Bausch Health Companies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devic…
Full company profileBausch Health Companies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bausch Health Companies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.67B | 8.72B | 8.38B | 8.60B | 8.03B | 8.43B | 8.12B | 8.76B | 9.63B | 10.3B | 11.1B |
| Gross Profit | 7.06B | 6.18B | 6.03B | 6.25B | 5.78B | 6.04B | 5.76B | 6.20B | 6.84B | 7.25B | 8.10B |
| Operating Income | 1.11B | 537M | 498M | 1.29B | 1.31B | 1.20B | 1.36B | 1.60B | 1.85B | 2.19B | 3.07B |
| EBITDA | - | 2.96B | 350M | 1.85B | 2.43B | 1.78B | 2.55B | 2.20B | 2.82B | 3.18B | 2.20B |
| Net Income | -2.41B | 2.40B | -4.15B | -1.79B | -560M | -948M | -225M | -592M | -46.0M | 157M | -972M |
| EPS | - | 6.89 | -12 | -5.07 | -1.58 | -2.64 | -0.62 | -1.62 | -0.13 | 0.42 | -2.60 |
| Balance Sheet | |||||||||||
| Total Assets | 43.5B | 37.5B | 32.5B | 33.9B | 31.2B | 29.2B | 25.7B | 27.4B | 26.5B | 26.4B | 25.5B |
| Total Liabilities | 40.3B | 31.6B | 29.7B | 32.7B | 30.6B | 29.2B | 25.4B | 27.4B | 26.8B | 26.0B | 25.8B |
| Shareholders' Equity | 3.15B | 5.85B | 2.73B | 1.06B | 535M | -106M | -692M | -1.02B | -1.28B | -554M | -1.33B |
| Cash & Short-term Investments | 542M | 720M | 721M | 3.24B | 605M | 582M | 564M | 947M | 1.18B | 1.31B | 2.49B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.09B | 2.29B | 1.50B | 1.50B | 1.11B | 1.43B | -728M | 1.12B | 1.60B | 1.40B | 2.29B |
| Capital Expenditure | 291M | 171M | 157M | 270M | 302M | 269M | 218M | 224M | 340M | 407M | 387M |
| Free Cash Flow | - | 1.95B | 1.27B | 1.22B | 802M | 1.14B | -996M | 893M | 1.26B | 993M | 1.90B |
| Ratios | |||||||||||
| ROE | -76.4% | 41.1% | -151.8% | -168.2% | -104.7% | - | - | - | - | - | - |
| ROA | -5.5% | 6.4% | -12.8% | -5.3% | -1.8% | -3.2% | -0.9% | -2.2% | -0.2% | 0.6% | -3.8% |
| Net Profit Margin | -24.9% | 27.6% | -49.5% | -20.8% | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% | -8.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bausch Health Companies Inc dividends
Bausch Health Companies Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Jan 10, 2000.
Who owns Bausch Health Companies Inc
- Insiders 11.12%
- Institutions 64.25%
- Public & others 24.63%
- Shares outstanding 374M
- Free float 261M
Bausch Health Companies Inc company profile
- Company name
- Bausch Health Companies Inc
- Ticker
- BVF.F
- ISIN
- CA0717341071
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 20,300
- Fiscal year end
- December
- Address
- 2150 St. Elzéar Blvd. West, Laval, QC, Canada, H7L 4A8
- Phone
- 514 744 6792
- Website
- bauschhealth.com
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc management
10- Mr. Thomas J. AppioCEO & Director · born 1962
- Mr. Jean-Jacques CharhonExecutive VP & CFO · born 1965
- Ms. Seana CarsonExecutive VP & General Counsel · born 1973
- Ms. Aimee J. LenarPresident of US Pharma · born 1976
- Mr. Mirza DautbegovicExecutive VP & COO
- Mr. Steven H. LeeSenior VP, Controller & Chief Accounting Officer · born 1971
- Mr. Garen SarafianVP & Head of Investor Relations
- Ms. Kathleen FitzpatrickExecutive VP and Chief HR & Communications Officer
- Mr. Cees HeimanSenior Vice President of Europe & Canada
- Ms. Jiny Kim M.B.A.Senior Vice President of Solta Medical · born 1977